New anticoagulants - promising and failed developments
New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safet...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
British journal of pharmacology
Year: 2011, Jahrgang: 165, Heft: 2, Pages: 363-372 |
| ISSN: | 1476-5381 |
| DOI: | 10.1111/j.1476-5381.2011.01578.x |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/j.1476-5381.2011.01578.x Verlag, Volltext: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.2011.01578.x 
|
| Verfasserangaben: | Job Harenberg, Svetlana Marx, Martin Krejczy and Martin Wehling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578428505 | ||
| 003 | DE-627 | ||
| 005 | 20230427065631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809r20122011xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1476-5381.2011.01578.x |2 doi | |
| 035 | |a (DE-627)1578428505 | ||
| 035 | |a (DE-576)508428505 | ||
| 035 | |a (DE-599)BSZ508428505 | ||
| 035 | |a (OCoLC)1341016454 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 245 | 1 | 0 | |a New anticoagulants - promising and failed developments |c Job Harenberg, Svetlana Marx, Martin Krejczy and Martin Wehling |
| 264 | 1 | |c 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 08 July 2011 | ||
| 500 | |a Gesehen am 09.08.2018 | ||
| 520 | |a New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safety profile. Rivaroxaban and dabigatran are approved for the post-operative prevention of thromboembolic complications after elective hip or knee replacement surgery; dabigatran is approved for the prevention of embolism in patients with atrial fibrillation in an increasing number of countries. Several novel indirect antithrombin-dependent anticoagulants as well as antithrombin-independent oral direct FXa and thrombin inhibitors are investigated in multiple indications for the prophylaxis and treatment of venous thromboembolism and the prophylaxis of arterial thrombotic disorders. Quality-adjusted life years costs and incremental cost-effectiveness ratios are relatively high at present, but may decrease after approval of more new anticoagulants for additional indications. | ||
| 534 | |c 2011 | ||
| 650 | 4 | |a anticoagulants | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a factor Xa inhibitors | |
| 650 | 4 | |a thrombin inhibitors | |
| 700 | 1 | |a Hetjens, Svetlana |d 1983- |e VerfasserIn |0 (DE-588)1031801979 |0 (DE-627)737600284 |0 (DE-576)379534223 |4 aut | |
| 700 | 1 | |a Krejczy, Martin |d 1987- |e VerfasserIn |0 (DE-588)1068281901 |0 (DE-627)820016349 |0 (DE-576)427604788 |4 aut | |
| 700 | 1 | |a Wehling, Martin |d 1957- |e VerfasserIn |0 (DE-588)129939331 |0 (DE-627)484463152 |0 (DE-576)297912577 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d Malden, MA : Wiley, 1946 |g 165(2012), 2, Seite 363-372 |h Online-Ressource |w (DE-627)324659016 |w (DE-600)2029728-2 |w (DE-576)094504113 |x 1476-5381 |7 nnas |a New anticoagulants - promising and failed developments |
| 773 | 1 | 8 | |g volume:165 |g year:2012 |g number:2 |g pages:363-372 |g extent:10 |a New anticoagulants - promising and failed developments |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1476-5381.2011.01578.x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.2011.01578.x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180809 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 129939331 |a Wehling, Martin |m 129939331:Wehling, Martin |d 60000 |d 65400 |e 60000PW129939331 |e 65400PW129939331 |k 0/60000/ |k 1/60000/65400/ |p 4 |y j | ||
| 998 | |g 1068281901 |a Krejczy, Martin |m 1068281901:Krejczy, Martin |d 60000 |d 65400 |e 60000PK1068281901 |e 65400PK1068281901 |k 0/60000/ |k 1/60000/65400/ |p 3 | ||
| 998 | |g 1031801979 |a Hetjens, Svetlana |m 1031801979:Hetjens, Svetlana |d 60000 |d 65400 |e 60000PH1031801979 |e 65400PH1031801979 |k 0/60000/ |k 1/60000/65400/ |p 2 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |d 65400 |e 60000PH108825507 |e 65400PH108825507 |k 0/60000/ |k 1/60000/65400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1578428505 |e 3020511909 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"relHost":[{"origin":[{"publisher":"Wiley ; Macmillan ; Nature Publ. Group","publisherPlace":"Malden, MA ; Basingstoke ; Basingstoke","dateIssuedKey":"1946","dateIssuedDisp":"1946-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 06.02.13"],"title":[{"title":"British journal of pharmacology","title_sort":"British journal of pharmacology","subtitle":"BJP online"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"324659016","disp":"New anticoagulants - promising and failed developmentsBritish journal of pharmacology","name":{"displayForm":["The British Pharmacological Society"]},"titleAlt":[{"title":"BJP online"}],"pubHistory":["1.1946 -"],"id":{"zdb":["2029728-2"],"doi":["10.1111/(ISSN)1476-5381"],"eki":["324659016"],"issn":["1476-5381"]},"part":{"pages":"363-372","text":"165(2012), 2, Seite 363-372","extent":"10","issue":"2","year":"2012","volume":"165"}}],"person":[{"family":"Harenberg","given":"Job","role":"aut","display":"Harenberg, Job"},{"family":"Hetjens","role":"aut","given":"Svetlana","display":"Hetjens, Svetlana"},{"display":"Krejczy, Martin","given":"Martin","role":"aut","family":"Krejczy"},{"display":"Wehling, Martin","given":"Martin","role":"aut","family":"Wehling"}],"title":[{"title_sort":"New anticoagulants - promising and failed developments","title":"New anticoagulants - promising and failed developments"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["First published: 08 July 2011","Gesehen am 09.08.2018"],"recId":"1578428505","physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Job Harenberg, Svetlana Marx, Martin Krejczy and Martin Wehling"]},"id":{"doi":["10.1111/j.1476-5381.2011.01578.x"],"eki":["1578428505"]}} | ||
| SRT | |a HARENBERGJNEWANTICOA2012 | ||